Bottom line
FHCLX vs XLV: the short answer
FHCLX (Health Care Portfolio) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
But FHCLX is far broader, holding 152 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 0.91% — a difference of $83 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +4.0% for FHCLX (reporting dates differ).
Updated Nov 19, 2026
FHCLX vs XLV side by side
| FHCLX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Fidelity | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.91% | 0.08% |
| Annual cost per $10k | $91 | $8 |
| 10-yr cost on $10k (prospectus) | $1,630 | $103 |
| Max front load | — | None |
| 12b-1 fee | 0.25% | 0.02% |
| 1-yr return | +14.4% | +14.5% |
| 5-yr return (annualized) | +4.0% | +8.1% |
| 10-yr return (annualized) | +9.0% | +9.8% |
| Best quarter | +22.2% | +14.5% |
| Worst quarter | −15.0% | −12.7% |
| Net assets (fund) | $5.8B | $40.6B |
| Number of holdings | 152 | 65 |
| Portfolio turnover | 69% | 2% |
| Returns as of | Feb 28, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHCLX | XLV | Difference |
|---|---|---|---|
| 2025 | +14.4% | +14.5% | −0.1% |
| 2024 | +4.9% | +2.5% | +2.4% |
| 2023 | +4.1% | +2.0% | +2.1% |
| 2022 | −12.8% | −2.1% | −10.8% |
| 2021 | +11.5% | +25.9% | −14.4% |
| 2020 | +24.4% | +13.3% | +11.2% |
| 2019 | +31.5% | +20.7% | +10.8% |
| 2018 | +7.4% | +6.3% | +1.1% |
| 2017 | +24.0% | +21.7% | +2.3% |
| 2016 | −10.7% | −2.8% | −7.9% |
Source: Fund prospectus bar charts
Holdings overlap
11 of FHCLX's top 25 holdings also appear in XLV's top 25.
| Holding | FHCLX | XLV |
|---|---|---|
| ELI LILLY and CO | 8.03% | 16.51% |
| Danaher Corp | 6.89% | 2.09% |
| JOHNSON and JOHNSON | 4.91% | 10.64% |
| Thermo Fisher Scientific Inc | 4.33% | 3.24% |
| Unitedhealth Group Inc | 3.49% | 6.57% |
| Gilead Sciences Inc | 2.21% | 2.73% |
| Boston Scientific Corp | 2.17% | 1.10% |
| Abbvie Inc | 2.03% | 7.74% |
| MERCK and CO INC | 1.60% | 5.52% |
| Cvs Health Corp | 1.29% | 2.30% |
| Cencora Inc | 1.14% | 0.96% |
Source: SEC Form N-PORT
FHCLX top 10
- ELI LILLY and CO — 8.03%
- Danaher Corp — 6.89%
- JOHNSON and JOHNSON — 4.91%
- Thermo Fisher Scientific Inc — 4.33%
- Unitedhealth Group Inc — 3.49%
- Alnylam Pharmaceuticals Inc — 2.40%
- Gilead Sciences Inc — 2.21%
- Boston Scientific Corp — 2.17%
- Ascendis Pharma A/s — 2.17%
- Fidelity Revere Street Trust — 2.17%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between FHCLX and XLV?
Which is cheaper, FHCLX or XLV?
Should I own both FHCLX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.